Author

B. C. Hann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Organism:mouse· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2

Frequent Co-Authors

A. P. Wiita· 3 shared I. D. Ferguson· 2 shared A. Atakilit· 1 shared A. B. Olshen· 1 shared A. Giddabasappa· 1 shared A. M. Thornton· 1 shared A. N. Brooks· 1 shared A. Renslo· 1 shared

Activity by Year

2017-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 11 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. P. Wiita

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Integrin αvβ8 on T cells is responsible for suppression of anti-tumor immunity in multiple syngeneic models and is a promising target for tumor immunotherapy

E. Dodagatta-Marri, H.-Y. Ma, B. Liang, J. Li, D. S. Meyer, K.-H. Sun, X. Ren, B. Zirak, M. D. Rosenblum, M. Headley, L. Pinzas, N. I. Reed, J. S. Del Cid, M. Adoumie, B. C. Hann, , D. Sheppard

This study shows that blocking integrin αvβ8 on T cells enhances anti-tumor immunity in multiple syngeneic models and is effective even when tumor cells do not express the integrin.

bioRxiv · May 14, 2020Cancer Biology

Exploiting KRAS-driven Ferroaddiction in Cancer Through Ferrous Iron-Activatable Drug Conjugates (FeADC)

H. Jiang, R. K. Muir, R. L. Gonciarz, A. B. Olshen, I. Yeh, B. C. Hann, N. Zhao, Y.-h. Wang, J. Korkola, S. C. Behr, M. J. Evans, e. collisson, A. Renslo

This paper develops FeADCs, ferrous iron-activatable drug conjugates, to target KRAS-driven cancers with improved tumor selectivity and systemic tolerability.

bioRxiv · May 12, 2020Cancer Biology

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis

V. Sarin, K. Yu, I. D. Ferguson, O. Gugliemini, M. A. Nix, B. C. Hann, M. Sirota, A. P. Wiita

This study evaluates how well multiple myeloma cell lines represent patient tumors using transcriptomic correlation analysis, finding significant variation in their similarity to patient tumors.

bioRxiv · Nov 20, 2019Cancer Biology

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

H. H.-L. Huang, I. D. Ferguson, A. M. Thornton, C. Y. T. Lam, Y.-H. T. Lin, P. Bastola, P. Choudhry, M. C. Mariano, M. D. Marcoulis, J. Malato, P. Phojanakong, T. G. Martin, J. L. Wolf, S. W. Wong, N. Shah, , A. P. Wiita

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.

bioRxiv · Feb 3, 2019Cancer Biology

Repurposing Tofacitinib As An Anti-Myeloma Therapeutic To Reverse Growth-Promoting Effects Of The Bone Marrow Microenvironment

C. Lam, M. Murnane, H. Liu, G. A. Smith, S. Wong, J. Taunton, J. O. Liu, C. S. Mitsiades, B. C. Hann, B. T. Aftab, A. P. Wiita

This paper validates tofacitinib as an effective anti-myeloma therapy by reversing bone marrow microenvironment-driven growth signals in vitro and in vivo.

bioRxiv · May 28, 2017Cancer Biology